Stiripentol is under clinical development by Biocodex and currently in Phase I for Renal Insufficiency. According to GlobalData, Phase I drugs for Renal Insufficiency does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Stiripentol LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Stiripentol overview
Stiripentol (Diacomit) is an anti-epileptic agent. It is formulated as hard gelatin capsules, suspension, powder for suspension, powder for solution for oral route of administration. It is indicated for use in conjunction with clobazam and valproate as adjunctive therapy of refractory generalized tonic-clonic seizures in patients with severe myoclonic epilepsy in infancy (SMEI, Dravet’s syndrome) whose seizures are not adequately controlled with clobazam and valproate.
Stiripentol (Diacomit) is under development for renal insufficiency and primary Hyperoxaluria Type 1, 2 and 3.
Stiripentol (Diacomit) was under development for the treatment of primary hyperoxaluria type 1, 2 and 3 in EU.
Biocodex overview
Biocodex is a pharmaceutical company that provides innovative healthcare solutions to women, men and children worldwide. The company develops and markets a wide range of products to meet patient needs, focusing on three pillars: Microbiota care, women’s health and orphan diseases. It offers products such as Saccharomyces Boulardii CNCM I-745, Saforelle and Stiripentol. The Saforelle, a specially designed cleansing product, that is expertise in vaginal microbiome; DIACOMIT, which treats Dravet syndrome. The company operates in Africa, the Amercia and Europe. Biocodex is headquartered in Paris, Ile-de-France, France.
For a complete picture of Stiripentol’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
